Phathom Pharmaceuticals, Inc. - Common Stock (PHAT)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -66.4%
- Revenue growing at 217% annually
Phathom Pharmaceuticals, Inc. - Common Stock (PHAT) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $770 million . Key value metrics: Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Phathom Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, PHAT shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -66.4% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.24.
StockPik's composite Value Score for PHAT is 54/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PHAT reports a high gross margin of 84.7% (sector average: 39.4%) and a negative operating margin of -96.4%.
PHAT shows revenue growing at 217% year-over-year, with earnings growing at 34%.